The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Sunitinib in Refractory Adrenocortical Carcinoma: A Phase II, Single-Arm, Open-Label Trial
Abstract
CONTEXT: Treatment of refractory adrenocortical carcinoma (ACC) is not established. Animal experiments pointed toward adrenal toxicity of sunitinib. OBJECTIVE: The objective of the study was to determine the antitumor effects of sunitinib in refractory ACC. DESIGN: This was a phase II, open-label trial using a two-stage accrual design. SETTING: The study was conducted at two tertiary referral centers. PATIENTS: Thirty-eight patients with refractory ACC progressing after mitotane and one to three cytotoxic chemotherapies participated in the study. INTERVENTION: The intervention included sunitinib at a standard dose (50 mg/d, 4 wk on, 2 wk off). MAIN OUTCOME MEASURE: Response was defined as progression-free survival (PFS) of 12 wk or longer (first tumor evaluation). RESULTS: Thirty-five patients could be evaluated for response. Five patients experienced stable disease, 24 had progressive disease, and six patients died from ACC before the first evaluation (naïve estimate five of 35=14.3%, median unbiased response rate 15.4%, 95% confidence interval 5.0-33.4%). The median PFS was 2.8 months. In responders, PFS ranged between 5.6 and 11.2 months and overall survival between 14.0 and 35.5 months. Of 36 serious adverse events, only nine were possibly related to sunitinib. Concomitant mitotane appeared to negatively impact on outcome. Furthermore, a negative correlation between the serum concentrations of sunitinib plus its active metabolite N-desethylsunitinib (SU12662) and mitotane (r=-0.650; P=0.114) was observed in seven evaluable patients suggestive of a relevant drug interaction. CONCLUSION: Sunitinib has modest activity in advanced refractory ACC, which compares favorably with other targeted treatments in these patients. Sunitinib serum levels might have been profoundly reduced by mitotane induced cytochrome P450-3A4 activity attenuating its antitumor activity and adverse effects. Together these findings suggest that sunitinib deserves further investigation in mitotane-naïve ACC patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A study using sunitinib, which is metabolized by CYP3A4, raised concerns that several of the study subjects did not reach therapeutic levels of this drug (302, 304).”
From Adrenocortical carcinoma (2014) · cites this paper as [304]
In the citing paper
“The reasons for these findings are induction of CYP3A4 by mitotane and metabolism of sunitinib by the same enzyme (301, 304).”
From Adrenocortical carcinoma (2014) · cites this paper as [304]
In the citing paper
“Interestingly, concomitant mitotane treatment negatively affected patient response, and sunitinib and mitotane levels were anticorrelated.”
From Adrenocortical carcinoma (2014) · cites this paper as [304]
In the citing paper
“A study using the multikinase inhibitor sunitinib led to stable disease in 5 of 35 patients (304).”
From Adrenocortical carcinoma (2014) · cites this paper as [304]
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S. M., Négrier, S., Szczylik, C. A., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,752
THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
Clopper, C. J., & Pearson, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,327
Demetri, G. D., van Oosterom, A. T., Garrett, C. R., Blackstein, M. E., Shah, M. H., Verweij, J., McArthur, G. A., Judson, I. R., Heinrich, M. C., Morgan, J. A., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69446-4 · Cited by 2,639
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
Raymond, É., Dahan, L., Raoul, J., Bang, Y., Borbath, I., Lombard‐Bohas, C., Valle, J. W., Metrakos, P. P., Smith, D. M., Vinik, A. I., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1003825 · Cited by 2,567
Faivre, S. J., Delbaldo, C., Vera, K., Robert, C., Lozahic, S., Lassau, N., Bello, C. L., DePrimo, S. E., Brega, N. M., Massimini, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2194 · Cited by 1,162
Sunitinib: From Rational Design to Clinical Efficacy
Chow, L. Q. M., & Eckhardt, S. G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.3602 · Cited by 894
Combination Chemotherapy in Advanced Adrenocortical Carcinoma
Faßnacht, M., Terzolo, M., Allolio, B., Baudin, É., Haak, H. R., Berruti, A., Welin, S., Schade‐Brittinger, C., Lacroix, A., Jarząb, B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200966 · Cited by 874
Icard, P., Goudet, P., Charpenay, C., Andreassian, B., Carnaille, B., Chapuis, Y., Cougard, P., Henry, J., & Proye, C. (2001) · World Journal of Surgery · doi:10.1007/s00268-001-0047-y · Cited by 543
Clinical pharmacokinetics of tyrosine kinase inhibitors
van Erp, N. P., Gelderblom, H., & Guchelaar, H.-J. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.08.004 · Cited by 503
Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?
Kebebew, E., Reiff, E., Duh, Q., Clark, O. H., & McMillan, A. (2006) · World Journal of Surgery · doi:10.1007/s00268-005-0329-x · Cited by 451
Abiven, G., Coste, J., Groussin, L., Anract, P., Tissier, F., Legmann, P., Dousset, B., Bertagna, X., & Bertherat, J. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2730 · Cited by 435
Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling
Giordano, T. J., Kuick, R., Else, T., Gauger, P. G., Vinco, M., Bauersfeld, J., Sanders, D., Thomas, D. G., Doherty, G., & Hammer, G. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1067 · Cited by 401
Adrenocortical carcinoma: a clinician’s update
Fassnacht, M., Libé, R., Kroiss, M., & Allolio, B. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.235 · Cited by 396
Clinical management of adrenocortical carcinoma
Fassnacht, M., & Allolio, B. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.10.008 · Cited by 349
Motzer, R. J., Hutson, T. E., Olsen, M. R., Hudes, G. R., Burke, J. M., Edenfield, W. J., Wilding, G., Agarwal, N., Thompson, J. A., Cella, D. F., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.4133 · Cited by 275
Prognostic parameters of metastatic adrenocortical carcinoma
Assié, G., Antoni, G., Tissier, F., Caillou, B., Abiven, G., Gicquel, C., Leboulleux, S., Travagli, J.-P., Dromain, C., Bertagna, X., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0706 · Cited by 236
Gicquel, C., BERTAGNA, X. Y., Schneid, H., Leblond‐Francillard, M., LUTON, J. P., Girard, F., & Bouc, Y. L. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.78.6.7911125 · Cited by 224
Giovanni Lughezzani, A., Sun, M., Perrotte, P., Claudio Jeldres, A., Alasker, A., Hendrik Isbarn, A., Budäus, L., Shariat, S. F., Guazzoni, G. F., Montorsi, F., et al. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2009.12.007 · Cited by 214
Hermsen, I. G., Fassnacht, M., Terzolo, M., Houterman, S., den Hartigh, J., Leboulleux, S., Daffara, F., Berruti, A., Chadarevian, R., Schlumberger, M., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2676 · Cited by 173
Self-citationMitotane for adrenocortical carcinoma treatment.
Hahner, S., & Faßnacht, M. (2005) · PubMed · Cited by 153
Treatment of Advanced Adrenocortical Carcinoma with Erlotinib plus Gemcitabine
Quinkler, M. O., Hahner, S., Wortmann, S., Johanssen, S., Adam, P., Ritte, C., Strasburger, C. J., Allolio, B., & Faßnacht, M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2564 · Cited by 149
Kroiss, M., Quinkler, M., Lutz, W. K., Allolio, B., & Fassnacht, M. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04214.x · Cited by 148
Veytsman, I. G., Nieman, L. K., & Fojo, T. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.2775 · Cited by 147
Berruti, A., Sperone, P., Ferrero, A., Germano, A., Ardito, A., Priola, A. M., Francia, S. D., Volante, M., Daffara, F., Generali, D., et al. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0918 · Cited by 138
Gross, D. J., Munter, G., Bitan, M., Siegal, T., Gabizón, A., Weitzen, R., Merimsky, O., Ackerstein, A., Salmon, A. Y., Sella, A., et al. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01124 · Cited by 136
Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma
Wortmann, S., Quinkler, M., Ritter, C., Kroiss, M., Johanssen, S., Hahner, S., Allolio, B., & Fassnacht, M. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0804 · Cited by 133
Self-citationMitotane has a strong and a durable inducing effect on CYP3A4 activity
van Erp, N. P., Guchelaar, H.-J., Ploeger, B. A., Romijn, J. A., Hartigh, J. D., & Gelderblom, H. (2011) · European Journal of Endocrinology · doi:10.1530/eje-10-0956 · Cited by 118
Contemporary Management of Adrenocortical Carcinoma
Laurent Zini, A., Porpiglia, F., & Faßnacht, M. (2011) · European Urology · doi:10.1016/j.eururo.2011.07.062 · Cited by 111
New targets and therapeutic approaches for endocrine malignancies☆
Fassnacht, M., Kreissl, M. C., Weismann, D., & Allolio, B. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.03.013 · Cited by 104
Honeywell, R. J., Yarzadah, K., Giovannetti, E., Losekoot, N., Smit, E. F., Walraven, M., Lind, J. S. W., Tibaldi, C., Verheul, H. M. W., & Peters, G. J. (2010) · Journal of Chromatography B · doi:10.1016/j.jchromb.2010.03.010 · Cited by 95
Patyna, S. J., Arrigoni, C., Terron, A., Kim, T., Heward, J. K., Vonderfecht, S. L., Denlinger, R. H., Turnquist, S. E., & Evering, W. (2008) · Toxicologic Pathology · doi:10.1177/0192623308326151 · Cited by 91
Endocrine side effects of broad-acting kinase inhibitors
Lodish, M. B., & Stratakis, C. A. (2010) · Endocrine Related Cancer · doi:10.1677/erc-10-0082 · Cited by 84
Samnotra, V., Vassilopoulou‐Sellin, R., Fojo, A. T., Oh, W. K., Larocca, R. V., Ernstoff, M. S., Memoli, V. A., Cole, B. F., Quinn, D. I., Simmons, P., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.15527 · Cited by 53
Sallah, S., Wan, J. Y., Nguyen, N. P., Vos, P. W., & Sigounas, G. (2001) · Cancer · doi:10.1002/1097-0142(20010915)92:6 · Cited by 47
Therapeutic Management of Advanced Adrenocortical Carcinoma: What Do We Know in 2011?
Baudin, É., Leboulleux, S., Ghuzlan, A. A., Chougnet, C., Young, J., Deandreis, D., Dumont, F., Dechamps, F., Caramella, C., Chanson, P., et al. (2011) · Hormones and Cancer · doi:10.1007/s12672-011-0094-2 · Cited by 42
Kroiß, M. (2011) · Frontiers in Endocrinology · doi:10.3389/fendo.2011.00027 · Cited by 37
Targeted Therapies for Adrenocortical Carcinoma: IGF and Beyond
Demeure, M. J., Bussey, K. J., & Kirschner, L. S. (2011) · Hormones and Cancer · doi:10.1007/s12672-011-0090-6 · Cited by 26
Estimation of o,p'-DDD in plasma by gas-liquid chromatography
Moolenaar, A. J., Niewint, J. W. M., & Oei, I. T. (1977) · Clinica Chimica Acta · doi:10.1016/0009-8981(77)90098-5 · Cited by 24
Flagged first, then by citations
Cited by
Sorted by citations
Faßnacht, M., Dekkers, O. M., Else, T., Baudin, É., Berruti, A., de Krijger, R. R., Haak, H. R., Mihai, R., Assié, G., & Terzolo, M. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0608 · Cited by 976
Else, T., Kim, A. C., Sabolch, A., Raymond, V. M., Kandathil, A., Caoili, E. M., Jolly, S., Miller, B. S., Giordano, T. J., & Hammer, G. D. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1029 · Cited by 892
Update in Adrenocortical Carcinoma
Faßnacht, M., Kroiß, M., & Allolio, B. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3020 · Cited by 414
Faßnacht, M., Berruti, A., Baudin, É., Demeure, M. J., Gilbert, J., Haak, H. R., Kroiß, M., Quinn, D. I., Hesseltine, E., Ronchi, C. L., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70081-1 · Cited by 342
PD-1 Blockade in Advanced Adrenocortical Carcinoma
Raj, N. P., Zheng, Y., Kelly, V., Katz, S. S., Chou, J. F., Do, R. K. G., Capanu, M., Zamarin, D., Saltz, L. B., Ariyan, C. E., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01586 · Cited by 208
Metadata
- Authors
- Kroiss, M., Quinkler, M., Johanssen, S., van Erp, N. P., Lankheet, N., Pöllinger, A., Laubner, K., Strasburger, C. J., Hahner, S., Müller, H.-H., Allolio, B., & Fassnacht, M.
- Affiliations
- University of Würzburg (DE)
- Slotervaartziekenhuis (NL)
- Charité – Universitätsmedizin Berlin (DE)
- Ludwig-Maximilians-Universität München (DE)
- Corresponding author
- Fassnacht, Martin
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2012-10
- Volume
- 97
- Issue
- 10
- Pages
- 3495-3503
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2072709644
- Cited by
- 175
- References
- 39
- Citations by year
- 2026: 5 · 2025: 13 · 2024: 10 · 2023: 6 · 2022: 14 · 2021: 15 · 2020: 13 · 2019: 15 · 2018: 16 · 2017: 7 · 2016: 13 · 2015: 16 · 2014: 15 · 2013: 15 · 2012: 1
- FWCI
- 15.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- sunitinib, adrenocortical carcinoma, refractory cancer, mitotane, drug interactions, CYP3A4, progression-free survival, targeted therapy, adverse events
- MeSH terms
- Sunitinib, Adrenal Cortex Neoplasms, Adult, Aged, Antineoplastic Agents, Drug Interactions, Female, Humans, Indoles, Male, Middle Aged, Mitotane, Pyrroles, Treatment Outcome, Adrenocortical Carcinoma, Disease Progression, Antineoplastic Agents, Hormonal, Drug Resistance, Neoplasm, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
